Molecular Changes in pp32 in Prostate Cancer
Abstract
Our previous work demonstrated that prostate cancers differ from benign prostatic epithelium in their expression of oncogenic members of the pp32 gene family. Whereas benign prostatic epithelium solely expresses pp32, a tumor suppressor, prostate cancers express pp32rl and pp32r2, which are oncogenic. The purpose of the study is to confirm and extend these preliminary results, to develop practical means to assay pp32 gene family members in clinical samples, and to determine the clinical significance of their presence. The approved proposal encompassed four broad tasks: 1 characterization of the pp32 expression phenotype of a larger sample of 40 prostatic adenocarcinomas; 2 development of a practical molecular pathology assay for altered pp32 transcripts; 3 adaptation of the assay to paraffin-embedded tissue; and 4 preliminary determination of the clinical utility of pp32rl and pp32r2 expression in prostatic adenocarcinoma. Unanticipated difficulties were encountered with the assay developed during the previous funding period. During the present funding period, a competitive quantitative PCR assay compatible with RNA from paraffin sections was developed. In the period beyond the funding period, these tools shall finally be applied to completion of Task 1 and Task 4.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2001
- Accession Number
- ADA407388
Entities
People
- Gary R. Pasternack
Organizations
- Johns Hopkins University